Nivolumab not costeffective for headandneck cancer

Nivolumab not costeffective for headandneck cancer PharmacoEconomics & Outcomes News 792, p21 - 2 Dec 2017 Nivolumab not cost effective for head and neck cancer Nivolumab does not appear to be cost effective for the treatment of recurrent or metastatic head and neck cancer (HNC), according to findings of a US study published in the Journal of the National Cancer Institute. A Markov model populated with data from the CheckMate 141 trial was used to evaluate the cost effectiveness of nivolumab compared with standard single-agent therapy in patients with platinum-resistant, recurrent or metastatic squamous cell head and neck cancer, from a US healthcare payer perspective over a 30-year time horizon. Cost effectiveness was evaluated from a societal perspective in the sensitivity analysis. Nivolumab was estimated to gain 0.400 additional QALYs compared with standard therapy at an incremental cost of $117 800, resulting in an incremental cost-effectiveness ratio (ICER) of $294 400 per QALY gained, which greatly exceeded the willingness-to-pay threshold of $100 000 per QALY gained. The cost-effectiveness model was sensitive to the cost of nivolumab; treatment was estimated to become cost effective if the drug cost was reduced by 71%, from $13 432 to $3931 per course. "While nivolumab substantially improves overall survival in patients with recurrent and metastatic HNC, this therapy is not a cost-effective treatment option at its current cost under a wide array of assumptions," concluded the authors. "While innovations in immunotherapy are promising, we must critically examine the financial and social impact of these therapies on patients and the health care system," they said. * 2017 US dollars Tringale KR, et al. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of the National Cancer Institute : 3 Nov 2017. Available from: URL: http://doi.org/10.1093/jnci/djx226 803284214 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Nivolumab not costeffective for headandneck cancer

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/nivolumab-not-costeffective-for-headandneck-cancer-bhrsDmKoWY
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4544-0
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p21 - 2 Dec 2017 Nivolumab not cost effective for head and neck cancer Nivolumab does not appear to be cost effective for the treatment of recurrent or metastatic head and neck cancer (HNC), according to findings of a US study published in the Journal of the National Cancer Institute. A Markov model populated with data from the CheckMate 141 trial was used to evaluate the cost effectiveness of nivolumab compared with standard single-agent therapy in patients with platinum-resistant, recurrent or metastatic squamous cell head and neck cancer, from a US healthcare payer perspective over a 30-year time horizon. Cost effectiveness was evaluated from a societal perspective in the sensitivity analysis. Nivolumab was estimated to gain 0.400 additional QALYs compared with standard therapy at an incremental cost of $117 800, resulting in an incremental cost-effectiveness ratio (ICER) of $294 400 per QALY gained, which greatly exceeded the willingness-to-pay threshold of $100 000 per QALY gained. The cost-effectiveness model was sensitive to the cost of nivolumab; treatment was estimated to become cost effective if the drug cost was reduced by 71%, from $13 432 to $3931 per course. "While nivolumab substantially improves overall survival in patients with recurrent and metastatic HNC, this therapy is not a cost-effective treatment option at its current cost under a wide array of assumptions," concluded the authors. "While innovations in immunotherapy are promising, we must critically examine the financial and social impact of these therapies on patients and the health care system," they said. * 2017 US dollars Tringale KR, et al. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of the National Cancer Institute : 3 Nov 2017. Available from: URL: http://doi.org/10.1093/jnci/djx226 803284214 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off